JP2011506442A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011506442A5 JP2011506442A5 JP2010537957A JP2010537957A JP2011506442A5 JP 2011506442 A5 JP2011506442 A5 JP 2011506442A5 JP 2010537957 A JP2010537957 A JP 2010537957A JP 2010537957 A JP2010537957 A JP 2010537957A JP 2011506442 A5 JP2011506442 A5 JP 2011506442A5
- Authority
- JP
- Japan
- Prior art keywords
- exendin
- formulation
- concentration
- pharmaceutical formulation
- conjugate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 111
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims description 86
- 238000009472 formulation Methods 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 55
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 49
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 48
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 40
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 32
- 235000018417 cysteine Nutrition 0.000 claims description 28
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 28
- 239000004472 Lysine Substances 0.000 claims description 27
- 108010011459 Exenatide Proteins 0.000 claims description 24
- 229960001519 exenatide Drugs 0.000 claims description 24
- 150000003573 thiols Chemical group 0.000 claims description 24
- 239000000872 buffer Substances 0.000 claims description 22
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 22
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 21
- 102000009027 Albumins Human genes 0.000 claims description 20
- 108010088751 Albumins Proteins 0.000 claims description 20
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 19
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 19
- 230000002473 insulinotropic effect Effects 0.000 claims description 19
- 239000011780 sodium chloride Substances 0.000 claims description 16
- 239000003381 stabilizer Substances 0.000 claims description 16
- 239000004094 surface-active agent Substances 0.000 claims description 15
- 230000003442 weekly effect Effects 0.000 claims description 15
- 239000002253 acid Substances 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 102000007562 Serum Albumin Human genes 0.000 claims description 11
- 108010071390 Serum Albumin Proteins 0.000 claims description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
- 239000008181 tonicity modifier Substances 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 9
- HQPMKSGTIOYHJT-UHFFFAOYSA-N ethane-1,2-diol;propane-1,2-diol Chemical group OCCO.CC(O)CO HQPMKSGTIOYHJT-UHFFFAOYSA-N 0.000 claims description 8
- 229920001993 poloxamer 188 Polymers 0.000 claims description 8
- BYKRNSHANADUFY-UHFFFAOYSA-M sodium octanoate Chemical group [Na+].CCCCCCCC([O-])=O BYKRNSHANADUFY-UHFFFAOYSA-M 0.000 claims description 8
- 235000001014 amino acid Nutrition 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 230000037430 deletion Effects 0.000 claims description 6
- 238000012217 deletion Methods 0.000 claims description 6
- 238000003780 insertion Methods 0.000 claims description 6
- 230000037431 insertion Effects 0.000 claims description 6
- 238000006467 substitution reaction Methods 0.000 claims description 6
- 150000001413 amino acids Chemical group 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical group [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 4
- 239000008351 acetate buffer Substances 0.000 claims description 4
- 239000008363 phosphate buffer Substances 0.000 claims description 4
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 229940068968 polysorbate 80 Drugs 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 230000002335 preservative effect Effects 0.000 claims description 4
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- 239000001632 sodium acetate Substances 0.000 claims description 4
- 235000017281 sodium acetate Nutrition 0.000 claims description 4
- 239000001488 sodium phosphate Substances 0.000 claims description 4
- 229910000162 sodium phosphate Inorganic materials 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 235000000346 sugar Nutrition 0.000 claims description 4
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 4
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical group [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 2
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 claims description 2
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000008297 liquid dosage form Substances 0.000 claims description 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 2
- 229960003105 metformin Drugs 0.000 claims description 2
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical group CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 2
- 125000005473 octanoic acid group Chemical group 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 239000007974 sodium acetate buffer Substances 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 239000012064 sodium phosphate buffer Substances 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 125000000185 sucrose group Chemical group 0.000 claims description 2
- 229940033663 thimerosal Drugs 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims 23
- 238000010168 coupling process Methods 0.000 claims 23
- 238000005859 coupling reaction Methods 0.000 claims 23
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 12
- FDBPJJZAGMWXFC-UHFFFAOYSA-N (2,5-dioxopyrrol-1-yl) propanoate Chemical compound CCC(=O)ON1C(=O)C=CC1=O FDBPJJZAGMWXFC-UHFFFAOYSA-N 0.000 claims 11
- 230000003914 insulin secretion Effects 0.000 claims 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 10
- 238000002360 preparation method Methods 0.000 claims 8
- WGJUFIXHTBAMBX-BYPYZUCNSA-N (2s)-2,6,6-triaminohexanoic acid Chemical group NC(N)CCC[C@H](N)C(O)=O WGJUFIXHTBAMBX-BYPYZUCNSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 239000006172 buffering agent Substances 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 38
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 24
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 10
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 0 CC1CCC[C@](*C(CC(N2CCC(NCCOCC*CC(NCCCCC(C(N)=O)NC)=O)=O)=O)C2=O)CCCCCCC1 Chemical compound CC1CCC[C@](*C(CC(N2CCC(NCCOCC*CC(NCCCCC(C(N)=O)NC)=O)=O)=O)C2=O)CCCCCCC1 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US734607P | 2007-12-11 | 2007-12-11 | |
| US2929508P | 2008-02-15 | 2008-02-15 | |
| US20087908P | 2008-12-03 | 2008-12-03 | |
| PCT/US2008/013599 WO2009075859A2 (en) | 2007-12-11 | 2008-12-11 | Formulation of insulinotropic peptide conjugates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011506442A JP2011506442A (ja) | 2011-03-03 |
| JP2011506442A5 true JP2011506442A5 (enExample) | 2013-06-13 |
Family
ID=40636823
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010537957A Withdrawn JP2011506442A (ja) | 2007-12-11 | 2008-12-11 | インスリン分泌性ペプチド結合体の製剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20090186819A1 (enExample) |
| EP (1) | EP2231191A2 (enExample) |
| JP (1) | JP2011506442A (enExample) |
| CN (1) | CN102026666B (enExample) |
| CA (1) | CA2708762A1 (enExample) |
| WO (1) | WO2009075859A2 (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090175821A1 (en) * | 1999-05-17 | 2009-07-09 | Bridon Dominique P | Modified therapeutic peptides with extended half-lives in vivo |
| US6514500B1 (en) * | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
| CA2638240C (en) * | 2008-08-29 | 2010-02-02 | Alexander Macgregor | Method of treating dysglycemia and glucose excursions |
| US20100092566A1 (en) * | 2008-10-15 | 2010-04-15 | Alessi Thomas R | Highly concentrated drug particles, formulations, suspensions and uses thereof |
| HUE068164T2 (hu) | 2008-10-17 | 2024-12-28 | Sanofi Aventis Deutschland | Egy inzulin és egy GLP-1 agonista kombinációja |
| EP3187877A1 (en) * | 2009-09-25 | 2017-07-05 | XOMA Technology Ltd. | Screening methods |
| SG10201500871TA (en) | 2009-11-13 | 2015-04-29 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist and methionine |
| CA2780460C (en) * | 2009-11-13 | 2018-09-04 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine |
| CN102939106B (zh) * | 2010-02-24 | 2016-06-29 | 艾瑞克有限公司 | 蛋白质制剂 |
| WO2011109784A1 (en) * | 2010-03-05 | 2011-09-09 | Conjuchem, Llc | Formulation of insulinotropic peptide conjugates |
| WO2011109787A1 (en) * | 2010-03-05 | 2011-09-09 | Conjuchem, Llc | Methods of administering insulinotropic peptides |
| BR112013001398A2 (pt) * | 2010-08-11 | 2016-05-24 | Kyowa Medex Co Ltd | método, reagente e kit para medir hemoglobina glicada |
| RS55378B1 (sr) | 2010-08-30 | 2017-03-31 | Sanofi Aventis Deutschland | Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2 |
| US9289516B2 (en) | 2011-03-09 | 2016-03-22 | The General Hospital Corporation | Imaging beta cell mass |
| CN102766204B (zh) * | 2011-05-05 | 2014-10-15 | 天津药物研究院 | 胰高血糖素样肽-1突变体多肽及其制备方法和其应用 |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| CN102854325B (zh) * | 2011-07-01 | 2015-01-07 | 复旦大学 | 胰岛素与血清蛋白可逆性结合的亲和力指标测定方法及应用 |
| BR112014004726A2 (pt) | 2011-08-29 | 2017-04-04 | Sanofi Aventis Deutschland | combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2 |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| CN102532303A (zh) * | 2011-12-22 | 2012-07-04 | 江苏弘和药物研发有限公司 | 聚乙二醇缀合的艾塞那肽的合成及应用 |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| PT2934568T (pt) | 2012-12-21 | 2018-01-04 | Sanofi Sa | Agonistas duplos de glp1/gip ou trigonais de glp1/gip/glucagina |
| TWI641381B (zh) | 2013-02-04 | 2018-11-21 | 法商賽諾菲公司 | 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物 |
| CN103408669B (zh) * | 2013-08-01 | 2016-01-20 | 江苏泰康生物医药有限公司 | Glp-1类似物融合蛋白，及其制备方法和用途 |
| CN103655468B (zh) * | 2013-12-02 | 2015-04-22 | 无锡和邦生物科技有限公司 | 一种促胰岛素分泌肽融合蛋白Exendin-4-HSA溶液稳定制剂 |
| TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／ｇｉｐ受體促效劑 |
| TW201609795A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| SG11201604706TA (en) | 2014-01-09 | 2016-07-28 | Sanofi Sa | Stabilized pharmaceutical formulations of insulin aspart |
| EP3091995B1 (en) | 2014-01-09 | 2024-03-20 | Sanofi | Stabilized pharmaceutical formulations of insulin aspart |
| WO2015104311A1 (en) | 2014-01-09 | 2015-07-16 | Sanofi | Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| CA2945681A1 (en) * | 2014-04-17 | 2015-10-22 | Merck Sharp & Dohme Corp. | Sitagliptin tannate complex |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| WO2016038521A1 (en) * | 2014-09-08 | 2016-03-17 | Sun Pharmaceutical Industries Limited | Pharmaceutical compositions of liraglutide |
| SI3542812T1 (sl) * | 2014-11-06 | 2021-04-30 | Xellia Pharmaceuticals Aps | Glikopeptidni sestavki |
| TWI758239B (zh) | 2014-12-12 | 2022-03-21 | 德商賽諾菲阿凡提斯德意志有限公司 | 甘精胰島素/利司那肽固定比率配製劑 |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| CN109562185A (zh) * | 2016-06-02 | 2019-04-02 | 赛诺菲 | 药剂与能够结合葡萄糖感应蛋白的部分的新颖缀合物 |
| EP3474820B1 (en) | 2017-08-24 | 2024-02-07 | Novo Nordisk A/S | Glp-1 compositions and uses thereof |
| CN111818971A (zh) | 2018-01-03 | 2020-10-23 | 梅德瑞斯糖尿病有限责任公司 | 用于治疗nash和其他紊乱的改进的肽药物 |
| CN108042794B (zh) * | 2018-01-05 | 2022-01-25 | 北京博康健基因科技有限公司 | 重组促胰岛素分泌素的稳定制剂及其制备方法 |
| TWI829687B (zh) | 2018-05-07 | 2024-01-21 | 丹麥商諾佛 儂迪克股份有限公司 | 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物 |
| CN116270504B (zh) * | 2019-04-26 | 2025-03-14 | 南京中硼联康医疗科技有限公司 | Bpa冻干制剂及制备方法 |
| PE20230819A1 (es) | 2020-02-18 | 2023-05-19 | Novo Nordisk As | Composiciones y usos de glp-1 |
| US20230210949A1 (en) * | 2020-05-22 | 2023-07-06 | Hanmi Pharm Co., Ltd. | Liquid formulation |
| CN112237571B (zh) * | 2020-10-26 | 2022-06-07 | 无锡和邦生物科技有限公司 | 一种提高艾塞那肽人血清白蛋白融合蛋白稳定性的冻干粉 |
| WO2022125598A1 (en) * | 2020-12-07 | 2022-06-16 | Spitfire Pharma Llc | Therapeutic regimens and methods for lowering blood glucose and or body weight using glp-1r and gcgr balanced agonists |
| US12171806B2 (en) | 2021-09-28 | 2024-12-24 | Spitfire Pharma Llc | Therapeutic regimens and methods for lowering blood glucose and/or body weight using GLP-1R and GCGR balanced agonists |
| US20240299500A1 (en) * | 2020-12-24 | 2024-09-12 | Hanmi Pharm Co., Ltd. | Combination therapy of insulinotropic peptide and glp-2, for preventing or treating short bowel syndrome |
| CN115819493A (zh) * | 2022-11-16 | 2023-03-21 | 河北常山生化药业股份有限公司 | 一种多肽固相合成方法 |
| AU2024310569A1 (en) * | 2023-06-26 | 2025-11-27 | AlbuNext, LLC | Albumin bound macromolecule tri-agonist activating glp-1/gip/glucagon receptors |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4462941A (en) * | 1982-06-10 | 1984-07-31 | The Regents Of The University Of California | Dynorphin amide analogs |
| US5120712A (en) * | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
| US5614492A (en) * | 1986-05-05 | 1997-03-25 | The General Hospital Corporation | Insulinotropic hormone GLP-1 (7-36) and uses thereof |
| US5118666A (en) * | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
| US5545618A (en) * | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| US5612034A (en) * | 1990-10-03 | 1997-03-18 | Redcell, Inc. | Super-globuling for in vivo extended lifetimes |
| US5843440A (en) * | 1990-10-03 | 1998-12-01 | Redcell Canada, Inc. | Cellular and serum protein anchors for modulating pharmacokinetics |
| DE69226077T2 (de) * | 1991-04-05 | 1998-12-03 | Genentech, Inc., South San Francisco, Calif. | PLAETTCHENAGGREGATIONSINHIBITOREN MIT HOHER SPEZIFIZITAET ZUM GP IIbIIIa |
| US5614487A (en) * | 1993-05-28 | 1997-03-25 | Genentech, Inc. | Sustained release pharmaceutical composition |
| US5705483A (en) * | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
| DK145493D0 (da) * | 1993-12-23 | 1993-12-23 | Dako As | Antistof |
| US5574008A (en) * | 1994-08-30 | 1996-11-12 | Eli Lilly And Company | Biologically active fragments of glucagon-like insulinotropic peptide |
| YU18596A (sh) * | 1995-03-31 | 1998-07-10 | Eli Lilly And Company | Analogne formulacije monomernog insulina |
| US5654276A (en) * | 1995-06-07 | 1997-08-05 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
| DK0915910T3 (da) * | 1996-06-05 | 2006-05-22 | Roche Diagnostics Gmbh | Exendin-analoger, fremgangsmåder til fremstilling deraf samt lægemidlter der indeholder disse |
| JP2001501593A (ja) * | 1996-08-08 | 2001-02-06 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 胃腸運動を調節するための方法 |
| WO1998011437A1 (en) * | 1996-09-16 | 1998-03-19 | Conjuchem, Inc. | Affinity labeling libraries with tagged leaving groups |
| UA65549C2 (uk) * | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| FR2757973B1 (fr) * | 1996-12-27 | 1999-04-09 | Sgs Thomson Microelectronics | Processeur de traitement matriciel |
| EP1629849B2 (en) * | 1997-01-07 | 2017-10-04 | Amylin Pharmaceuticals, LLC | Pharmaceutical compositions comprising exendins and agonists thereof |
| US6723530B1 (en) * | 1997-02-05 | 2004-04-20 | Amylin Pharmaceuticals, Inc. | Polynucleotides encoding proexendin, and methods and uses thereof |
| US7157555B1 (en) * | 1997-08-08 | 2007-01-02 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
| US6437092B1 (en) * | 1998-11-06 | 2002-08-20 | Conjuchem, Inc. | Conjugates of opioids and endogenous carriers |
| DE69839946D1 (de) * | 1997-11-07 | 2008-10-09 | Conjuchem Biotechnologies Inc | Methoden zum Screening von Affinitätsmarker-Bibliotheken |
| US7223725B1 (en) * | 1997-11-14 | 2007-05-29 | Amylin Pharmaceuticals, Inc. | Exendin agonist compounds |
| WO1999043708A1 (en) * | 1998-02-27 | 1999-09-02 | Novo Nordisk A/S | Glp-1 derivatives of glp-1 and exendin with protracted profile of action |
| US6107489A (en) * | 1998-03-17 | 2000-08-22 | Conjuchem, Inc. | Extended lifetimes in vivo renin inhibitors |
| US6998387B1 (en) * | 1998-03-19 | 2006-02-14 | Amylin Pharmaceuticals, Inc. | Human appetite control by glucagon-like peptide receptor binding compounds |
| US20030170250A1 (en) * | 1998-03-23 | 2003-09-11 | Ezrin Alan M. | Local delivery of long lasting therapeutic agents |
| AU777564B2 (en) * | 1999-01-14 | 2004-10-21 | Amylin Pharmaceuticals, Inc. | Novel exendin agonist formulations and methods of administration thereof |
| DK1143989T3 (da) * | 1999-01-14 | 2007-04-16 | Amylin Pharmaceuticals Inc | Exendiner til glucagonundertrykkelse |
| US6451974B1 (en) * | 1999-03-17 | 2002-09-17 | Novo Nordisk A/S | Method of acylating peptides and novel acylating agents |
| US6924264B1 (en) * | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
| US6849714B1 (en) * | 1999-05-17 | 2005-02-01 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| DE60000665T3 (de) * | 1999-05-17 | 2009-10-29 | ConjuChem Biotechnologies Inc., Montreal | Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen |
| US20040266673A1 (en) * | 2002-07-31 | 2004-12-30 | Peter Bakis | Long lasting natriuretic peptide derivatives |
| US6329336B1 (en) * | 1999-05-17 | 2001-12-11 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
| US6887470B1 (en) * | 1999-09-10 | 2005-05-03 | Conjuchem, Inc. | Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components |
| US7144854B1 (en) * | 1999-09-10 | 2006-12-05 | Conjuchem, Inc. | Long lasting anti-angiogenic peptides |
| US6514500B1 (en) * | 1999-10-15 | 2003-02-04 | Conjuchem, Inc. | Long lasting synthetic glucagon like peptide {GLP-!} |
| US6506724B1 (en) * | 1999-06-01 | 2003-01-14 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
| DE60036367T2 (de) * | 1999-06-21 | 2008-05-29 | Eli Lilly And Co., Indianapolis | Synergitische verwendung von thiazolidinedionen und glucagon-ähnlichem peptid-1 und dessen agonisten für die behandlung von nicht-insulin-abhängigen diabetes |
| US6528486B1 (en) * | 1999-07-12 | 2003-03-04 | Zealand Pharma A/S | Peptide agonists of GLP-1 activity |
| US6706892B1 (en) * | 1999-09-07 | 2004-03-16 | Conjuchem, Inc. | Pulmonary delivery for bioconjugation |
| US7090841B1 (en) * | 2000-05-01 | 2006-08-15 | The Board Of Regents Of The University Of Texas System | Use of CD63 inhibitors |
| WO2001089554A2 (en) * | 2000-05-19 | 2001-11-29 | Bionebraska, Inc. | Treatment of acute coronary syndrome with glp-1 |
| NZ519752A (en) * | 2000-10-20 | 2005-04-29 | Amylin Pharmaceuticals Inc | Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide |
| CN101696240A (zh) * | 2001-02-02 | 2010-04-21 | 康久化学生物技术公司 | 长效生长激素释放因子衍生物 |
| WO2002066511A2 (en) * | 2001-02-16 | 2002-08-29 | Conjuchem Inc. | Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders |
| DE10114178A1 (de) * | 2001-03-23 | 2002-10-10 | Aventis Pharma Gmbh | Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität |
| EP1390399B1 (en) * | 2001-05-31 | 2005-05-11 | Conjuchem, Inc. | Long lasting fusion peptide inhibitors for hiv infection |
| AU2002364586A1 (en) * | 2001-12-21 | 2003-07-30 | Delta Biotechnology Limited | Albumin fusion proteins |
| US7105489B2 (en) * | 2002-01-22 | 2006-09-12 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating polycystic ovary syndrome |
| US6861236B2 (en) * | 2002-05-24 | 2005-03-01 | Applied Nanosystems B.V. | Export and modification of (poly)peptides in the lantibiotic way |
| EP1575490A4 (en) * | 2002-06-04 | 2007-08-08 | Lilly Co Eli | MODIFIED ANALOGUES OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) |
| EP1684793B1 (en) * | 2003-11-13 | 2011-09-21 | Novo Nordisk A/S | Pharmaceutical composition comprising an insulinotropic glp-1(7-37) analogue, asp(b28)-insulin, and a surfactant |
| CN101665538A (zh) * | 2003-12-18 | 2010-03-10 | 诺沃挪第克公司 | 与白蛋白样物质相连的新glp-1类似物 |
| PT1745078E (pt) * | 2004-04-23 | 2009-09-17 | Conjuchem Biotechnologies Inc | Método para a purificação de conjugados de albumina |
| CN112618700A (zh) * | 2004-11-12 | 2021-04-09 | 诺和诺德公司 | 促胰岛素肽的稳定制剂 |
| WO2007053946A1 (en) * | 2005-11-09 | 2007-05-18 | Conjuchem Biotechnologies Inc. | Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin |
-
2008
- 2008-12-11 EP EP08859460A patent/EP2231191A2/en not_active Withdrawn
- 2008-12-11 JP JP2010537957A patent/JP2011506442A/ja not_active Withdrawn
- 2008-12-11 CN CN2008801265943A patent/CN102026666B/zh active Active
- 2008-12-11 US US12/333,276 patent/US20090186819A1/en not_active Abandoned
- 2008-12-11 WO PCT/US2008/013599 patent/WO2009075859A2/en not_active Ceased
- 2008-12-11 CA CA2708762A patent/CA2708762A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011506442A5 (enExample) | ||
| JP6685343B2 (ja) | 持続型インスリン分泌性ペプチド結合体の液状製剤 | |
| CN102026666B (zh) | 促胰岛素肽缀合物制剂 | |
| ES2715326T3 (es) | Formulación liquida de conjugado de insulina de acción prolongada | |
| TWI630214B (zh) | 長效胰島素及胰促泌素肽之液體製劑 | |
| CN104884045B (zh) | 包括胃泌酸调节素和免疫球蛋白片段的蛋白质缀合物的液体制剂 | |
| ES2974001T3 (es) | Composición para el tratamiento de la diabetes que comprende un conjugado de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada | |
| ES2949553T3 (es) | Composición para el tratamiento de la diabetes, que contiene conjugado de análogo de insulina de acción prolongada y conjugado de péptido de secreción de insulina de acción prolongada | |
| WO2011109787A1 (en) | Methods of administering insulinotropic peptides | |
| WO2011109784A1 (en) | Formulation of insulinotropic peptide conjugates | |
| JP6549104B2 (ja) | 持続型ヒト成長ホルモン製剤 | |
| US10441665B2 (en) | Liquid formulation of long acting insulinotropic peptide conjugate | |
| CN104870469A (zh) | 药物组合物 | |
| TWI882569B (zh) | TACI-Fc融合蛋白液體藥物製劑 | |
| HK1204565B (en) | A liquid formulation of long acting insulinotropic peptide conjugate | |
| BR112015001735B1 (pt) | Formulação líquida de conjugado de peptídeo insulinotrópico de ação de longa duração |